adding polatuzumab vedotin (pola) to bendamustine and rituximab (br) treatment improves survival in patients with relapsed/refractory dlbcl result of a phase 2 clinical trial | AVESİS

Ankara Üniversitesi Akademik Veri Yönetim Sistemi

adding polatuzumab vedotin (pola) to bendamustine and rituximab (br) treatment improves survival in patients with relapsed/refractory dlbcl result of a phase 2 clinical trial

Atıf İçin Kopyala

23TH EHA, 11 - 15 Haziran 2018

Yayın Türü: Bildiri / Tam Metin Bildiri
Ankara Üniversitesi Adresli: Evet